Jasper shares ral­ly as chron­ic hives drug scores in small, ear­ly tri­al

Jasper Ther­a­peu­tics’ an­ti-c-KIT an­ti­body has shown promise in a Phase 1b/2a test in peo­ple with cer­tain ir­ri­ta­ble skin con­di­tions, send­ing its shares ris­ing on Mon­day …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER